axinn

FDA's Longtime Approach to New Chemical Entity Designations No Codified

PUBLICATIONS | LESS THAN 1 MIN READ

June 14, 2021 By: Ramya Auroprem Outsourced Pharma and Pharmaceutical Online

Axinn associate Ramya Auroprem co-authored the <u>Outsourced Pharma</u> and <u>Pharmaceutical</u> <u>Online</u> article, "FDA's Longtime Approach to New Chemical Entity Designations Now Codified."

Related People



Ramya Auroprem

To subscribe to our publications, <u>click here</u>.

Featured Insights

- GCR Live: Law Leaders Europe 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
 SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
 WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts Champions of the Arts Awards and Gala 2025 **SPONSORSHIP** ANTITRUST
- NJSBA Annual Meeting and Convention 2025
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies Making Paragraph IV Litigation Work for You
 - WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
 sponsorship ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
 AXINN VIEWPOINTS LITIGATION & TRIALS